Pre-made Tebentafusp biosimilar ( scFv Fusion, anti-CD3E therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-555
Anti-CD3E therapeutic antibody (Pre-made Tebentafusp biosimilar,scFv Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
The drug, tebentafusp, is a type of treatment called a bispecific fusion protein. It works by helping immune cells get close enough to cancer cells to attack them. The clinical trial evaluated the drug as an initial treatment for people with metastatic uveal melanoma.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CD3E therapeutic antibody (Pre-made Tebentafusp biosimilar,scFv Fusion)|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Malignant melanoma;Uveal melanoma|